Form 4: Redmile Group Reports Acquisition of IGM Biosciences Stock as Director Compensation

Redmile Group, a significant shareholder in IGM Biosciences, reports acquiring additional shares as part of director compensation.

Summary

• Redmile Group, LLC, and Jeremy Green reported changes in beneficial ownership of IGM Biosciences, Inc. stock on June 28, 2024.
• The transaction involved the acquisition of 1,734 shares of common stock at $0.00, representing a quarterly retainer paid in stock to Mr. Michael Lee, a managing director of Redmile and a board member of IGM Biosciences.
• Following the transaction, Redmile Group's beneficial ownership increased to 3,080,066 shares.
• Mr. Lee holds these securities as a nominee on behalf of Redmile and has assigned all economic, pecuniary, and voting rights to Redmile.
• Jeremy Green, as the principal of Redmile, may also be deemed to beneficially own the reported securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports a routine transaction related to director compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of shares reflects ongoing investment and confidence in IGM Biosciences by a major shareholder, Redmile Group.

Management Comments

• Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Comparison to Industry Standards

• Director compensation in the form of stock is a common practice in the biotechnology industry to align the interests of directors with those of shareholders.
• Redmile Group's holdings in IGM Biosciences are substantial, indicating a significant investment and influence in the company's direction.
• Similar filings are regularly made by other major shareholders and insiders in publicly traded biotech companies such as Amgen, Gilead Sciences, and Biogen.

Related Party Transactions

• The transaction involves a related party, Michael Lee, a managing director of Redmile Group and a member of the Board of Directors of IGM Biosciences, receiving stock as compensation.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence as it reflects continued investment by a major shareholder.

Key Dates